Constructive Bio appoints biopharma leader Jim Weissman to its Board of Directors
Constructive Bio, a leading synthetic biology company, today announces the appointment of Jim Weissman to its Board of Directors.
Constructive Bio Partners with RxCelerate to Advance ncAA-Containing Biologics Through Drug Design and Development
Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities,…
Constructive Bio Selected as Nature Biotechnology 2025 Editor’s Pick for Synthetic Genomics and ncAA Platform
Constructive Bio was selected by Nature Biotechnology as a 2025 Editor’s Pick, recognising the company’s synthetic genomics platform and use…
